Literature DB >> 21304107

Density enhanced phosphatase-1 down-regulates urokinase receptor surface expression in confluent endothelial cells.

Patrick M Brunner1, Patricia C Heier, Judit Mihaly-Bison, Ute Priglinger, Bernd R Binder, Gerald W Prager.   

Abstract

VEGF(165), the major angiogenic growth factor, is known to activate various steps in proangiogenic endothelial cell behavior, such as endothelial cell migration and invasion, or endothelial cell survival. Thereby, the urokinase-type plasminogen activator (uPA) system has been shown to play an essential role not only by its proteolytic capacities, but also by induction of intracellular signal transduction. Therefore, expression of its cell surface receptor uPAR is thought to be an essential regulatory mechanism in angiogenesis. We found that uPAR expression on the surface of confluent endothelial cells was down-regulated compared with subconfluent proliferating endothelial cells. Regulation of uPAR expression was most probably affected by extracellular signal-regulated kinase 1/2 (ERK1/2) activation, a downstream signaling event of the VEGF/VEGF-receptor system. Consistently, the receptor-like protein tyrosine phosphatase DEP-1 (density enhanced phosphatase-1/CD148), which is abundantly expressed in confluent endothelial cells, inhibited the VEGF-dependent activation of ERK1/2, leading to down-regulation of uPAR expression. Overexpression of active ERK1 rescued the DEP-1 effect on uPAR. That DEP-1 plays a biologic role in angiogenic endothelial cell behavior was demonstrated in endothelial cell migration, proliferation, and capillary-like tube formation assays in vitro.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21304107      PMCID: PMC3087537          DOI: 10.1182/blood-2010-09-307694

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  47 in total

1.  A new mathematical model for relative quantification in real-time RT-PCR.

Authors:  M W Pfaffl
Journal:  Nucleic Acids Res       Date:  2001-05-01       Impact factor: 16.971

2.  Domain 1 of the urokinase receptor (uPAR) is required for uPAR-mediated cell binding to vitronectin.

Authors:  N Sidenius; F Blasi
Journal:  FEBS Lett       Date:  2000-03-17       Impact factor: 4.124

Review 3.  Mechanisms of angiogenesis and arteriogenesis.

Authors:  P Carmeliet
Journal:  Nat Med       Date:  2000-04       Impact factor: 53.440

4.  An extracellular ligand increases the specific activity of the receptor-like protein tyrosine phosphatase DEP-1.

Authors:  M Sörby; J Sandström; A Ostman
Journal:  Oncogene       Date:  2001-08-23       Impact factor: 9.867

5.  Urokinase receptor expression on human microvascular endothelial cells is increased by hypoxia: implications for capillary-like tube formation in a fibrin matrix.

Authors:  M E Kroon; P Koolwijk; B van der Vecht; V W van Hinsbergh
Journal:  Blood       Date:  2000-10-15       Impact factor: 22.113

6.  NAB2, a corepressor of EGR-1, inhibits vascular endothelial growth factor-mediated gene induction and angiogenic responses of endothelial cells.

Authors:  Markus Lucerna; Diana Mechtcheriakova; Alexandra Kadl; Gernot Schabbauer; Romana Schäfer; Florian Gruber; Yuri Koshelnick; Horst-Dietmar Müller; Katja Issbrücker; Matthias Clauss; Bernd R Binder; Erhard Hofer
Journal:  J Biol Chem       Date:  2002-11-08       Impact factor: 5.157

7.  A mutant receptor tyrosine phosphatase, CD148, causes defects in vascular development.

Authors:  Takamune Takahashi; Keiko Takahashi; Patricia L St John; Paul A Fleming; Takuya Tomemori; Toshio Watanabe; Dale R Abrahamson; Christopher J Drake; Takuji Shirasawa; Thomas O Daniel
Journal:  Mol Cell Biol       Date:  2003-03       Impact factor: 4.272

8.  Suppression of urokinase receptor expression by bikunin is associated with inhibition of upstream targets of extracellular signal-regulated kinase-dependent cascade.

Authors:  Hiroshi Kobayashi; Mika Suzuki; Naohiro Kanayama; Takashi Nishida; Masaharu Takigawa; Toshihiko Terao
Journal:  Eur J Biochem       Date:  2002-08

9.  Direct binding of Nur77/NAK-1 to the plasminogen activator inhibitor 1 (PAI-1) promoter regulates TNF alpha -induced PAI-1 expression.

Authors:  Florian Gruber; Peter Hufnagl; Renate Hofer-Warbinek; Johannes A Schmid; Johannes M Breuss; Renate Huber-Beckmann; Markus Lucerna; Nikolina Papac; Hanna Harant; Ivan Lindley; Rainer de Martin; Bernd R Binder
Journal:  Blood       Date:  2002-12-27       Impact factor: 22.113

10.  Contact inhibition of VEGF-induced proliferation requires vascular endothelial cadherin, beta-catenin, and the phosphatase DEP-1/CD148.

Authors:  Maria Grazia Lampugnani; Adriana Zanetti; Monica Corada; Takamune Takahashi; Giovanna Balconi; Ferruccio Breviario; Fabrizio Orsenigo; Anna Cattelino; Rolf Kemler; Thomas O Daniel; Elisabetta Dejana
Journal:  J Cell Biol       Date:  2003-05-26       Impact factor: 10.539

View more
  16 in total

1.  VEGF-induced endothelial cell migration requires urokinase receptor (uPAR)-dependent integrin redistribution.

Authors:  Revu Ann Alexander; Gerald W Prager; Judit Mihaly-Bison; Pavel Uhrin; Stefan Sunzenauer; Bernd R Binder; Gerhard J Schütz; Michael Freissmuth; Johannes M Breuss
Journal:  Cardiovasc Res       Date:  2012-01-26       Impact factor: 10.787

2.  Immunocytochemical and biochemical detection of the urokinase-type plasminogen activator receptor (uPAR) in the rat tooth germ and in lipid rafts of PMA-stimulated dental epithelial cells.

Authors:  A von Germar; K Barth; W Schwab
Journal:  Histochem Cell Biol       Date:  2013-06-09       Impact factor: 4.304

Review 3.  Lipid rafts: integrated platforms for vascular organization offering therapeutic opportunities.

Authors:  Anna Laurenzana; Gabriella Fibbi; Anastasia Chillà; Giancarlo Margheri; Tommaso Del Rosso; Elisabetta Rovida; Mario Del Rosso; Francesca Margheri
Journal:  Cell Mol Life Sci       Date:  2015-01-01       Impact factor: 9.261

Review 4.  Angiogenesis in cancer: Anti-VEGF escape mechanisms.

Authors:  Gerald W Prager; Marina Poettler; Matthias Unseld; Christoph C Zielinski
Journal:  Transl Lung Cancer Res       Date:  2012-03

Review 5.  VEGF-initiated angiogenesis and the uPA/uPAR system.

Authors:  Johannes M Breuss; Pavel Uhrin
Journal:  Cell Adh Migr       Date:  2012-10-17       Impact factor: 3.405

6.  Domain 2 of uPAR regulates single-chain urokinase-mediated angiogenesis through β1-integrin and VEGFR2.

Authors:  Gretchen A Larusch; Alona Merkulova; Fakhri Mahdi; Zia Shariat-Madar; Robert G Sitrin; Douglas B Cines; Alvin H Schmaier
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-05-24       Impact factor: 4.733

7.  CRISPR/Cas9 uPAR Gene Knockout Results in Tumor Growth Inhibition, EGFR Downregulation and Induction of Stemness Markers in Melanoma and Colon Carcinoma Cell Lines.

Authors:  Alessio Biagioni; Anastasia Chillà; Mario Del Rosso; Gabriella Fibbi; Francesca Scavone; Elena Andreucci; Silvia Peppicelli; Francesca Bianchini; Lido Calorini; Anna Li Santi; Pia Ragno; Francesca Margheri; Anna Laurenzana
Journal:  Front Oncol       Date:  2021-05-14       Impact factor: 6.244

8.  Characterization of the endothelial cell cytoskeleton following HLA class I ligation.

Authors:  Mary E Ziegler; Puneet Souda; Yi-Ping Jin; Julian P Whitelegge; Elaine F Reed
Journal:  PLoS One       Date:  2012-01-11       Impact factor: 3.240

9.  Differential uPAR recruitment in caveolar-lipid rafts by GM1 and GM3 gangliosides regulates endothelial progenitor cells angiogenesis.

Authors:  Francesca Margheri; Laura Papucci; Nicola Schiavone; Riccardo D'Agostino; Silvana Trigari; Simona Serratì; Anna Laurenzana; Alessio Biagioni; Cristina Luciani; Anastasia Chillà; Elena Andreucci; Tommaso Del Rosso; Giancarlo Margheri; Mario Del Rosso; Gabriella Fibbi
Journal:  J Cell Mol Med       Date:  2014-10-14       Impact factor: 5.310

10.  A computational model predicting disruption of blood vessel development.

Authors:  Nicole Kleinstreuer; David Dix; Michael Rountree; Nancy Baker; Nisha Sipes; David Reif; Richard Spencer; Thomas Knudsen
Journal:  PLoS Comput Biol       Date:  2013-04-04       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.